Quarterly ResultMay 12, 2026, 04:07 PM
SELLAS Q1 Net Loss $(8.4)M; Cash $107.1M; $150M ATM Program
AI Summary
SELLAS Life Sciences Group reported a net loss of $(8.4) million for the three months ended March 31, 2026, an increase from $(5.8) million in the prior year period. Despite the increased loss, the company significantly boosted its cash position, ending the quarter with $107.1 million in cash and cash equivalents, up from $71.8 million at December 31, 2025, primarily due to $44.1 million from warrant exercises. SELLAS also initiated a new $150.0 million at-the-market equity offering program in March 2026 and expects its current cash to fund operations for at least the next twelve months.
Key Highlights
- Q1 2026 net loss was $(8.4) million, up from $(5.8) million in Q1 2025.
- Net loss per share improved to $(0.05) in Q1 2026 from $(0.07) in Q1 2025.
- Cash and cash equivalents rose to $107.1 million as of March 31, 2026.
- Received $44.1 million from warrant exercises in Q1 2026.
- Entered a new $150.0 million at-the-market equity offering program.
- R&D expenses increased to $5.1 million in Q1 2026 from $3.2 million in Q1 2025.
- Accumulated deficit reached $283.4 million as of March 31, 2026.